Nymox Pharmaceutical Corporation (NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
The Company now intends to meet with authorities and to proceed to file where possible in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories.
BP = Big Pharma, a generic term for very big drug companies who potentially buy up/partner with good IP, i.e. NX-1207, in this context.
Most of the historical trading volume for this company happened after that date and virtually every one of those is a winner, like me for instance with a 1.50 average. You on the other hand is the loser who due to his simplistic ignorance turned his nose up then on that bargain and was then forced to pay 2.50 later for his shares. Don't worry though because in the grand scheme of things you are still early too ;-).
No-one loses straight away but ultimately XPOINT is going to put new disruptive pressure on FLASH makers. FLASH makers will have to keep ahead of XPOINT on (lower) cost and capacity to stay relevant because on performance and life-span they are now SOL ! ;-)
Thanks, I appreciate your posts too. The way to summarize where this new technology fits in is as follows, the data hierarchy of a computer has just now changed to the following ...
REGISTERS / CACHE / MEMORY / E-DRAM / XPOINT / FLASH / HARD-DRIVE
in descending order of latency and ascending order of capacity.
It will NOT make DRAM obsolete, it will complement it as the first fast line of non-volatile storage. SRAM/DRAM i.e. cache/main memory basically have infinite rewrite-ability capability unlike XPoint so you would not want to waste an Xpoint drive using it as memory as it would not last very long. However XPoint will displace all other hard-drive/flash storage as the the quickest offline storage linked first to memory, it's basically a permanent very fast cache for hard-drives. It will smooth out the computing latency response experience so your computer will always feel fast.
'XPoint is a breakthrough in HPC.'
I believe it will also be a breakthrough in PC/Server and eventually mobile technology. The capacity of the original chip, 16 GB, is big enough to put a Windows o/s on it along with program executables. The implication is enormous, basically you can eliminate the seconds lag you get when loading a new application because XPoint is so fast like SRAM cache. So the PC experience will become a much more consistently fast experience as if all programs are consistently in memory. Putting the o/s on Xpoint will also make PCs/Servers more resilient as it has a much lower wear rate compared to hard drives/SSDs. In time as capacity rises it can replace flash drives on phones and tablets giving them a speed boost too. This is truly awesome ground-breaking innovation as you would expect from Intel.
Good call. Shorts will be even more concerned around $3 when they all start panicking and heading for the exits all at once, but that is for the coming days .... ;-)
'After that the judge will hear arguments and decide if there are grounds for a class action '
yeah like that is going to happen ... I find ISR guilty of accurately quoting from the study which it linked to lol. What there will be grounds for class action is against AF for putting out a slanderous article with clear lies in it. I want Babcock to nail that bstard hard for ISR shareholders and the whole industry who's had to put up with his despicable manipulation over the years !
Are you involved in this field ? How big do you think is the BPH market for NX-1207 eventually ? Also what do you think of it being used as a cancer treatment as well ?
Thanks doc for that nice summary. It's obvious if you think about it, NX-1207 has provided genuine relief i.e. worked in every test done of it, how likely was it that doing nothing (i.e. placebo) would also genuinely provide relief to an equal extent ? IIRC In Ph II they did not filter out properly other subsequent alternate treatments taken by this placebo control group which they then went back and did.
just waiting for this initial charade to be over so it can then be changed into a $100m+ cross-complaint against AF/Street. Can't wait, got my popcorn ready.
So NX-1207 is a protein natural (bad) cell killer. Seem like a Silver Bullet to me ;-).
Our lead drug candidate, NX-1207, is a selective pro-apoptotic protein that when injected into the prostate causes localized cell death and tissue loss without harming adjacent tissues. Apoptosis is a natural form of programmed cell death routinely used by the human body to eliminate unneeded cells without releasing harmful substances into the surrounding area.
We are currently developing NX-1207 as a focal treatment for low grade localized prostate cancer. Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. About 1 in 6 men will be diagnosed with prostate cancer during their lifetime. Most cases of prostate cancer are detected via prostate-specific antigen (PSA) screening and usually found to be localized tumors.
There is an unmet need for a safe and effective treatment of low grade localized prostate cancer. Surgical removal of the prostate (radical prostatectomy) and radiation therapy with or without androgen deprivation therapy are the most common active treatment options for localized prostate cancer but can have significant short- and long- term adverse effects, including impotence, urinary dysfunction, and other complications. The alternative is to choose active surveillance without active treatment. This avoids the risks of active treatment but has its own serious drawbacks, including anxiety associated with living with cancer and the uncertainties surrounding the risk of progression, particularly for men in their 50s and 60s with many years of life expectancy ahead. The drop-out rate from active surveillance can range from 1/3 to ½ of men with low grade localized prostate cancer. NX-1207 represents a potential safe and effective treatment of low grade localized prostate cancer. Preclinical studies of NX-1207 showed strongly positive results in laboratory studies of human prostate cancer.
ASBROUCK HEIGHTS, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66. The financing consisted of a private placement of 400,000 shares with a European investor at $1.25 per share and an equity line drawdown from the Company's existing facility consisting of 217,122 shares priced at $1.66 per share. There were no warrants attached to the transactions.
$10 has been my conservative estimate for after approval but I have seen good analyses that say it could be as high as $50 eventually.
You timed the trough well and in real-time.You also switched from short to long at the right time too. No quibbles about your trading just some of the inane rambling nonsense you post most of the time.